Currently, several ICI clinical trials conducted in the field of advanced HCC have shown that the objective response rate (ORR) of PD-1/PD-L1 inhibitor monotherapy can reach 10–20%, and is safe and reliable [31]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.